Live Briefing · Sem.6 día 4 Vol. I · Núm. 034

JUE · 25.JUN.2026 Lima — Perú 07:45 UTC-5

CAMEX · FDA SERVICES DIVISION

FDA Briefing
Diario.

Edición № 034. Sem.6 día 4 · Labeling + Claims framework · Section 609. Cuarto del quartet operativo MoCRA (Registration · Substantiation · AER · Labeling). Section 609 mandates: domestic contact info + fragrance allergen disclosure + professional-use statement + ingredient INCI naming. La fragrance allergen rule esperada NPRM mayo 2026. Hoy: 5 labeling requirements + cosmetic vs drug claims + LatAm specific risks + formaldehyde-releasers ban impact.

Edición

№ 034

CoberturaLabeling + Claims

FocoSection 609 + drug line

FormatoDoctrine + comparative

Próxima edición26.JUN.2026 (vie)

Sem.6 · día 4 · cuarto del quartet

Con № 034 cerramos el quartet operativo MoCRA: Registration (031) + Safety Substantiation (032) + AER (033) + Labeling (034). Section 609 es la obligation más visible del quartet — every package en mercado USA exhibits labeling daily. Pero también es la más operativamente compleja: 5+ distinct requirements + pending fragrance allergen rule + cosmetic-vs-drug claim distinction + INCI naming + state-level overlay (California Prop 65). Para LatAm cosmetics exporters, labeling failures son la causa más común de port-of-entry detention — más que substantive safety issues.

U.S. FDA · MoCRA Section 609 · Cosmetic Labeling Requirements · Fair Packaging and Labeling Act SECTION 609

Obligation

Section 609 · enforceable

Fragrance rule

★ NPRM esperada MAY 2026

Claims framework

Drug-cosmetic line crítica

Port detention risk

★ Causa #1 LatAm

Labeling + Claims · Section 609 · cuarto pilar MoCRA

Lo que dice tu producto. Quién responde. Qué claim hace.

Section 609 de MoCRA establece el framework de labeling más significativo en cosmetics USA en 85+ años. Las requirements specificas: (α) domestic contact information mandatory — USA-based address, phone, o electronic contact for adverse event reporting; (β) fragrance allergen disclosure — pending FDA rule esperada NPRM mayo 2026, identificación individual de allergens vs generic “fragrance”; (γ) professional-use-only labeling — statement “Administered or used only by licensed professionals” para products restricted; (δ) INCI naming required — International Nomenclature, common names violation; (ε) net contents font size — specific height requirements per package size.

Lo crítico operativamente para LatAm: port-of-entry detention por labeling failures es la causa #1 de problemas para LatAm cosmetics exporters. Más común que substantive safety issues. Most detentions ocurren no porque producto es “dangerous” sino porque está “misbranded”. Common LatAm errors: drug claims (“treats acne”, “cures eczema”), bilingual labels sin English translation completa, font size violations, missing USA contact info, color additive nomenclature incorrecta (“CI 15850” vs “Red 7 Lake”). El cost de label correction post-detention: $20K-100K+ por shipment. El cost de proactive label audit: $2K-10K. Cost-benefit overwhelmingly favorable. Plus: state-level expansion (California Prop 65, NY “clean beauty”, state-specific clean labeling) creates compliance overlay adicional que federal alone no captures.

609

section MoCRA
labeling requirements

specific requirements
active + pending

26+

fragrance allergens EU
likely FDA template

causa de port-of-entry
detention LatAm

Las 5 noticias Section 609 del día

Selección Camex · Curado 25.JUN.2026 · 07:30

015 reqs

Section 609 5 requirements Active + pending

Los 5 requirements · activos hoy · pendientes 2026.

Section 609 de MoCRA establece 5 distinct labeling requirements con timing diferente. Activos hoy: (α) domestic contact information — USA-based address, phone, o electronic contact info on label for AE reporting (mandatory + enforceable); (γ) professional-use-only statement — “Administered or used only by licensed professionals” si applicable; (δ) INCI naming compliance — International Nomenclature standardized names, not common names. Pending: (β) fragrance allergen disclosure — FDA proposed rule esperada mayo 2026 NPRM; (ε) net contents standards — FPLA + 21 CFR 701 (active pero updates esperados).

Para LatAm exporters, el requirement con highest LatAm-specific impact es (α) domestic contact info. Foreign manufacturers sin USA presence direct must designate USA-based Responsible Person + contact info on label. Common LatAm gap: contact info es manufacturer Latin American directly (Mexican phone, Brasilian email) instead of USA Responsible Person contact. Esto renders product technically misbranded. Plus: contact info debe ser monitored regularly + responsive — actual customer/regulator contact must reach Responsible Person dentro de reasonable time. Phone que no responde, email que bounces, address obsoleta = labeling failure during inspection or FDA verification.

“Domestic contact info no es just compliance checkbox — es operationally functional requirement. Phone que no responde, email que bounces, address obsoleta = labeling failure operational, no documentation.” — Camex · doctrina contact info

▲ Impacto LatAm

LatAm cosmetics exporters con labels mostrando manufacturer-side contact (Latin American phone/email/address): technically misbranded bajo MoCRA. Common pattern: legacy labels desde pre-MoCRA era cuando regulation no requería USA contact. Update needed across product portfolio — every SKU sold a USA requires label revision. Investment label refresh: $500-2K per SKU. Vs port-of-entry detention cost $20K-100K. Cost-benefit favorable.

✓ Acción Camex recomendada

Label audit comprehensive para LatAm cosmetics portfolio: (α) verify USA-based domestic contact info on every SKU sold a USA, (β) confirm contact is functional + monitored + responsive, (γ) verify INCI naming compliance ingredient-by-ingredient, (δ) check professional-use-only statements donde applicable, (ε) net contents font size verification per package. Annual label audit + update protocol. Camex articula label audit framework + bilingual review.

Fuente: MoCRA Section 609 · 21 USC §364e · Fair Packaging and Labeling Act · 21 CFR 701 · FDA Guidance for Cosmetic Industry

5 requirements · status mapping

4 de 5 requirements active hoy. α domestic contact info es highest LatAm-specific impact — common gap en legacy labels pre-MoCRA.

02Fragrance

Pending NPRM May 2026 expected 26+ EU allergens template

Fragrance allergens · NPRM may 2026 · prepare ahora.

FDA está required by MoCRA to issue regulations identifying fragrance allergens que must be disclosed en cosmetic product labels, plus threshold levels. Statutory deadline era 29 junio 2024 — ya passed. FDA’s Spring 2025 Unified Agenda flagged NPRM esperada mayo 2026. As of January 2026, FDA had not yet issued rule. Once issued, many products will require labeling changes + potentially reformulation o marketing strategy adjustments.

El framework esperado: FDA likely templated en EU Cosmetics Regulation (EC 1223/2009) que lists 26+ fragrance allergens requiring individual disclosure when exceeding thresholds (typically 0.001% rinse-off, 0.01% leave-on). Common allergens en la EU list: Limonene, Linalool, Citral, Geraniol, Coumarin, Eugenol, Cinnamal, Citronellol, Hydroxycitronellal, Farnesol, Benzyl Salicylate, Benzyl Alcohol, y más. Para LatAm cosmetics exporters, preparación ahora es crítica: (α) request allergen breakdowns from fragrance suppliers (esto puede toma weeks-meses), (β) inventory fragrance components per SKU, (γ) identify likely allergens en formulations, (δ) prepare label revision templates, (ε) coordinate reformulation discussions si threshold concerns. Companies waiting until rule finalized may be unable to reprint labels fast enough.

“FDA fragrance allergen rule está coming. Waiting for finalization means insufficient time para label refresh. Preparation now is competitive advantage — late-movers paying rushed-implementation premium.” — Camex · doctrina fragrance preparation

▲ Impacto LatAm

LatAm cosmetics manufacturers con fragrance components — particularly Brasil natural perfumes, Mexican color cosmetics con scented variants, Argentinian fragrance industry, Peruvian botanical products: fragrance allergen disclosure impacts portfolio significantly. Even “natural” o “essential oil-based” fragrances contain allergens (limonene en citrus oils, linalool en lavender, citral en lemongrass). Pre-preparation: request allergen breakdowns from fragrance suppliers + audit formulations + plan label revisions proactively.

✓ Acción Camex recomendada

Fragrance allergen pre-preparation framework: (α) request “Allergen Breakdown” certificates de fragrance suppliers (todos los SKUs), (β) inventory fragrance components per product, (γ) cross-reference contra EU 26+ allergen list as proxy, (δ) calculate threshold concentrations, (ε) prepare label revision templates pendientes FDA rule finalization, (ζ) reformulation analysis si threshold concerns. Camex coordinates con fragrance suppliers + reformulation expertise.

Fuente: FDA Unified Agenda Spring 2025 · RIN 0910-AI90 · MoCRA Section 612 · EU Cosmetics Regulation EC 1223/2009 reference · Crowell & Moring analysis

26+ allergens · EU template likely FDA

26+ EU allergens likely FDA template. “Natural” no exempt — essential oils contain allergens at thresholds requiring disclosure. Botanical LatAm impacted.

03Drug line

Drug claims trigger Cosmetic vs drug Class action exposure

La línea cosmetic-drug: where claims become regulatory.

El distinción cosmetic-vs-drug es uno de las áreas más operativamente complejas de FDA regulation cosmetics. Por definition: cosmetics intended for cleansing, beautifying, promoting attractiveness, o altering appearance. Drugs intended for diagnosis, cure, mitigation, treatment, o prevention of disease, o to affect structure/function of the body. La línea es blurry pero strictly enforced. Marketing claims trigger drug classification — incluso si product ingredient profile is identical to other cosmetics.

Claims que trigger drug classification: “treats acne” (acne is disease → drug), “cures eczema” (eczema is disease → drug), “prevents aging” (affects body structure → drug), “reverses wrinkles” (affects body structure → drug), “removes scars” (affects body structure → drug), “kills bacteria” (antibacterial drug claim), “stops hair loss” (drug claim). Claims safe para cosmetic: “cleanses”, “moisturizes”, “improves appearance”, “softens skin”, “enhances natural beauty”, “reduces appearance of fine lines” (note “appearance” qualifier). El distinction matters porque drug classification triggers completely different regulatory regime: NDA (New Drug Application) o OTC Monograph requirement, much higher compliance burden, vastly more expensive ($10M-100M+ for NDA). Plus: consumer class action plaintiffs aggressively litigate cosmetic claims — “all natural”, “non-toxic”, “organic”, “clean beauty” all face litigation as implicit safety claims requiring substantiation. Combined: drug claims trigger FDA enforcement, soft claims trigger class action litigation.

“Drug claims trigger FDA enforcement. Soft claims trigger class action. Cosmetics must navigate narrow channel between both. ‘Appearance’ qualifier is the operational distinction.” — Camex · doctrina claims framework

▲ Impacto LatAm

LatAm cosmetics marketing materials translated del Spanish/Portuguese a English often preserve “treats” “cures” “prevents” language que perfectly OK en Latin American markets pero trigger drug classification in USA. Common LatAm patterns: skincare claiming to “tratar arrugas” → “treats wrinkles” (drug claim); hair products claiming “previene caída” → “prevents hair loss” (drug claim); skin products claiming “cura manchas” → “cures dark spots” (drug claim). Translation review specifically claim-focused mandatory before USA market entry.

✓ Acción Camex recomendada

Claims framework audit para LatAm cosmetics: (α) inventory marketing claims actual per SKU (labels + packaging + e-commerce + advertising), (β) classify each claim cosmetic-safe vs drug-trigger, (γ) reformulate language as needed con “appearance” qualifier, (δ) substantiation review para claims kept (“dermatologist-tested” requires testing records), (ε) state-level overlay check (CA Prop 65, NY “clean beauty”). Camex articula bilingual claims framework + Spanish-English translation review.

Fuente: FD&C Act cosmetic definition · 21 USC §321(i) · FDA Guidance Industry · class action litigation precedents · Foley & Lardner analysis

Claims framework · safe vs risky

2 columnas, 2 worlds. “Treats”, “cures”, “prevents”, “reverses” trigger drug. “Appearance” qualifier saves claim — operative distinction.

04Hair smooth

Formaldehyde ban NPRM December 2025 ★ LatAm hair smoothing

Formaldehyde-releasers ban: hair smoothing LatAm crisis.

FDA’s Unified Agenda flagged diciembre 2025 NPRM para prohibit formaldehyde + formaldehyde-releasing chemicals en hair smoothing/straightening products. La propuesta target chemicals como methylene glycol, formalin, paraform, glyoxal, glyoxylic acid y otros releasers que generate formaldehyde when heated durante styling. Health concerns: respiratory irritation, dermatitis, sensitization, potential carcinogenicity. Targeted products: Brazilian smoothing treatments, keratin treatments, hair relaxers professional + consumer-grade.

Para LatAm, este es el regulatory move con highest sectoral impact en cosmetics history reciente. Brazilian smoothing treatments son categoría exportadora major LatAm a USA market — billions en revenue annually, primarily serving Hispanic + African-American consumer markets. Hair smoothing/straightening con formaldehyde-releasers genera repeated AE reports documented: chemical burns, severe scalp irritation, respiratory issues, hair loss. Para LatAm hair smoothing manufacturers (primarily Brasil, Centroamérica): reformulation roadmap urgent. Alternative chemistries: glyoxylic acid (potentially also restricted), thio-based reducers (longer-term safer), enzymatic treatments (emerging). Each requires R&D investment + reformulation timeline 12-24 meses.

“Formaldehyde-releasers ban es regulatory move con highest LatAm impact en cosmetics. Brazilian smoothing category essentially restructured. Reformulation roadmap urgent.” — Camex · doctrina hair smoothing ban

▲ Impacto LatAm

LatAm hair smoothing/straightening manufacturers — particularly Brasil (largest exporter), Centroamérica, Caribe: category restructure required. Current product lines con formaldehyde-releasers will be misbranded/adulterated under final rule. Reformulation timeline 12-24 meses standard. R&D investment $200K-2M+ depending on portfolio scope. Plus: existing inventory + already-distributed product remediation. Coordinated industry response advisable.

✓ Acción Camex recomendada

Hair smoothing reformulation roadmap para LatAm exporters: (α) audit current portfolio for formaldehyde-releasers, (β) R&D alternative chemistry pathways (glyoxylic vs thio-based vs enzymatic), (γ) consumer testing alternative formulations, (δ) gradual product line transition timeline 12-24 meses, (ε) communication strategy con USA importers + retailers. Camex coordinates con cosmetics chemists + R&D partners + USA Hispanic market communication.

Fuente: FDA Unified Agenda Spring 2025 RIN 0910-AI83 · MoCRA Section 612 · December 2025 NPRM expected · Registrar Corp analysis · hair smoothing AE literature

Hair smoothing · ban impact LatAm

Hair smoothing category essentially restructured. Brasil largest exporter affected. Alternative chemistries available pero reformulation 12-24 meses.

05State overlay

State-level expansion CA Prop 65 + NY + WA “Clean beauty”

State overlay: federal compliance no es enough.

MoCRA establishes federal floor — pero state-level cosmetics legislation continues expansion, creando overlay regulatory framework adicional. California Prop 65: requires warning labels para products containing chemicals known cancer/reproductive toxicity (lead, mercury, PFAS, parabens, phthalates). New York “clean beauty” legislation: 1,4-dioxane restrictions, expanded ingredient transparency. Washington State: heavy metals restrictions cosmetics. Vermont, Hawaii, Maryland: PFAS-specific restrictions emerging. Federal MoCRA compliance is necessary but not sufficient para multi-state distribution.

Para LatAm exporters, el state-level overlay tiene operational implications específicas: (α) California Prop 65 warning labels often required incluso si federal label compliant — separate warning statement obligation; (β) state-specific ingredient restrictions may force reformulation o regional product variants; (γ) “clean beauty” claims subject to state attorney general enforcement + consumer class action; (δ) bilingual labeling requirements some states require additional language compliance; (ε) state-specific reporting some states require independent registration. Compliance strategy: federal floor + state overlay — Camex approach. Single-state distribution: federal compliance + relevant state. Multi-state distribution: federal compliance + cumulative state overlay (typically California, NY, WA most stringent).

“Federal MoCRA es floor, no ceiling. CA, NY, WA add layers. Cumulative state overlay determines final compliance burden. Federal-only strategy fails durante multi-state distribution.” — Camex · doctrina state overlay

▲ Impacto LatAm

LatAm cosmetics exporters con multi-state USA distribution (typical pattern Hispanic market exposure): cumulative state requirements create complex compliance matrix. California Prop 65 alone has 800+ listed chemicals — many appear en cosmetic formulations. Hispanic markets often concentrated en California (largest Hispanic state), Texas (less restrictive), Florida (less restrictive), New York (Prop 65-like), Illinois (less restrictive). Compliance matrix per state per product. Sin matrix approach, exposure asimétrica.

✓ Acción Camex recomendada

State-by-state compliance matrix para LatAm cosmetics: (α) inventory states con product distribution, (β) identify state-specific cosmetics restrictions per state, (γ) cross-reference contra portfolio ingredients, (δ) develop state-specific label variants si needed, (ε) state-specific monitoring routine for emerging legislation. Camex articula multi-state compliance framework + Prop 65 specifically.

Fuente: California Proposition 65 · NY clean beauty legislation · WA cosmetics restrictions · multi-state legislative tracking · ArrSys 2026 guide

State overlay · 5 stricter states

Cumulative state overlay. California + NY most restrictive. LatAm Hispanic market concentrated en CA = elevated compliance burden vs less-restrictive states.

Quartet MoCRA operativo · cerrado hoy

4 días · 4 obligations · framework completo

4 obligations · 4 ediciones · doctrine completa.

Sem.6 arc cosmetics

№ 031 · LUNI

REGISTRATION

Facility registration

Section 607. Biennial renewal cycle 1 (1 jul 2026 · 6 días). 14,000+ facilities globally. ~8% LatAm. Form 5066 + FEI + Cosmetics Direct portal.

№ 032 · MARII

SUBSTANTIATION

Safety substantiation

Section 608. Adequate substantiation requirement sin FDA guidance 3+ años. 6 pillars industry-converged. ε CPSR weak link LatAm. Records access vía Section 610.

№ 033 · MIÉIII

AER

Adverse events

Section 605. 15 business days desde first awareness. Enforceable desde dic 2023. 7 categorías “serious”. 6 años records. AEMS Public Dashboard transparente.

№ 034 · JUEIV

LABELING

Labeling + claims · HOY

Section 609. 5 requirements (4 active, 1 pending). Drug claims line crítica. State overlay (CA Prop 65, NY clean). Port detention causa #1 LatAm.

Las 5 requirements · Section 609 detalladas

Active + pending · operational checklist

Cada requirement · su scope · su status.

Section 609 framework

Domestic contact info

USA-based address, phone, o electronic contact for AE reporting. Most-violated LatAm requirement. Foreign manufacturers must designate Responsible Person USA-side.

StatusACTIVE

Fragrance allergens

Individual allergen disclosure. FDA NPRM esperada mayo 2026. EU template likely (26+ allergens, 0.001%/0.01% thresholds). Preparation now critical.

StatusPENDING

Professional-use statement

“Administered or used only by licensed professionals” statement para products restricted. Salon-strength chemical peels, professional hair treatments, etc.

StatusACTIVE

INCI naming

International Nomenclature standardized names. “Tocopherol” not “Vitamin E”. “Butyrospermum Parkii Butter” not “Shea Butter”. Common names violation.

StatusACTIVE

Net contents

Specific font size requirements per package size. 1/16th inch wrong = detention. FPLA + 21 CFR 701 governing. Color additives US-certified naming.

StatusACTIVE

Claims framework · cosmetic vs drug line

Decision matrix · litigation exposure

Lo que puedes decir · lo que no puedes.

Marketing claims framework

✓ SAFE COSMETIC CLAIMS

Lo que puedes decir

Claims focused en appearance, sensation, cleansing function. No therapeutic claims. “Appearance” qualifier saves potentially problematic claims.

Cleanses + moisturizes

Improves appearance

Softens skin

Reduces appearance of fine lines

Enhances natural beauty

Soothes + refreshes

✗ DRUG CLAIMS · TRIGGER

Lo que no puedes decir

Claims que diagnose, treat, prevent disease o affect body structure. Triggers drug classification = NDA o OTC Monograph required. Class action exposure parallel.

Treats acne · cures eczema

Prevents aging · reverses wrinkles

Removes scars · heals dark spots

Kills bacteria · anti-fungal

Stops hair loss · regrows hair

Prevents disease + medical conditions

5 risks específicos LatAm · labeling + claims

Sectorial exposure mapping

5 risks LatAm-específicos · operativos.

Camex defensive doctrine

BILINGUAL ERRORS

Spanish-English translation

“Tratar arrugas” → “treats wrinkles” preserves drug claim verbatim. Direct translation often imports drug-trigger language from Latin American marketing. Translation review claim-focused mandatory.

HAIR SMOOTHING

Formaldehyde category

Brazilian smoothing + keratin treatments + hair relaxers facing imminent NPRM ban. Reformulation 12-24 meses. Brasil + Centroamérica + Caribe exposed primarily.

CONTACT INFO

Legacy labels

Labels desde pre-MoCRA era con manufacturer Latin American contact info. Technically misbranded under MoCRA. Portfolio refresh required across all SKUs. $500-2K per SKU.

“NATURAL” CLAIMS

Botanical marketing

“All natural”, “100% natural”, “non-toxic” claims trigger class action. LatAm botanical positioning (Peruvian, Brasilian, Mexican natural) exposed. Substantiation requirements stricter post-MoCRA.

STATE OVERLAY

California Prop 65

Hispanic market concentrated California (largest Hispanic state). Prop 65 warning labels often required incluso si federal compliant. 800+ listed chemicals impact cosmetic formulations frequently.

★ INSIGHT CAMEX

Los 5 risks operan en combinación · not isolated. Bilingual translation errors (α) + drug claims (γ con safe vs risky) compound. Hair smoothing ban (β) + “all natural” claims (δ) on same product = double exposure. California Prop 65 (ε) requires separate warning incluso si federal compliant. Combined defense: bilingual claim review + reformulation roadmap + label refresh + Prop 65 warning + ongoing state monitoring. Investment $20K-100K per portfolio scope. Vs port-of-entry detention $20K-100K+ per shipment + customer loss + class action exposure. Cost-benefit decisively favorable. Camex articula bilingual labeling framework + state overlay specifically Hispanic market.

Quartet cerrado. 4 obligations. 4 ediciones. 1 doctrine.

Sem.6 días 1-4 cerraron el quartet operativo MoCRA: Registration (031) + Substantiation (032) + AER (033) + Labeling+Claims (034). Doctrine completa para LatAm cosmetics manufacturers serviendo USA market. Each obligation interconnected: facility registered enables product listing enables substantiation records enables AE reporting enables labeling compliance. Sin uno, los otros 3 fail operationally. Plus fragrance allergen rule pending (NPRM mayo 2026), hair smoothing ban pending (NPRM dic 2025), state overlay expanding continuously. Para LatAm: bilingual translation review + hair smoothing reformulation roadmap + legacy label refresh + state-by-state compliance matrix. Camex articula quartet integrado + Phase 2 GMP preparation (Sem.6 día 5 mañana?) o sectorial-specific deep dives. La pregunta estructural permanece: cuándo invertir en compliance integrado, not si.

Ediciones acumuladas en la serie

6 días

Hasta MoCRA renewal deadline

+ 200

Empresas articuladas con Camex

Camex · FDA Briefing · Sem.6 día 4 · Quartet cerrado Edición № 034 · 25.JUN.2026 · Próxima: 26.JUN.2026 (vie · Weekend Watch VI) Vol I · № 034

Lo que dice tu producto. Quién responde. Qué claim hace.

Las 5 noticias Section 609 del día

Los 5 requirements · activos hoy · pendientes 2026.

Fragrance allergens · NPRM may 2026 · prepare ahora.

La línea cosmetic-drug: where claims become regulatory.

Formaldehyde-releasers ban: hair smoothing LatAm crisis.

State overlay: federal compliance no es enough.

Quartet MoCRA operativo · cerrado hoy

4 obligations · 4 ediciones · doctrine completa.

Facility registration

Safety substantiation

Adverse events

Labeling + claims · HOY

Las 5 requirements · Section 609 detalladas

Cada requirement · su scope · su status.

Domestic contact info

Fragrance allergens

Professional-use statement

INCI naming

Net contents

Claims framework · cosmetic vs drug line

Lo que puedes decir · lo que no puedes.

5 risks específicos LatAm · labeling + claims

5 risks LatAm-específicos · operativos.

Spanish-English translation

Formaldehyde category

Legacy labels

Botanical marketing

California Prop 65

Quartet cerrado. 4 obligations. 4 ediciones. 1 doctrine.

Leave A Comment Cancelar la respuesta

ENLACES

PROGRAMAS

CONTACTANOS

Lo que dice tu producto. Quién responde. Qué claim hace.

Las 5 noticias Section 609 del día

Los 5 requirements · activos hoy · pendientes 2026.

Fragrance allergens · NPRM may 2026 · prepare ahora.

La línea cosmetic-drug: where claims become regulatory.

Formaldehyde-releasers ban: hair smoothing LatAm crisis.

State overlay: federal compliance no es enough.

Quartet MoCRA operativo · cerrado hoy

4 obligations · 4 ediciones · doctrine completa.

Facility registration

Safety substantiation

Adverse events

Labeling + claims · HOY

Las 5 requirements · Section 609 detalladas

Cada requirement · su scope · su status.

Domestic contact info

Fragrance allergens

Professional-use statement

INCI naming

Net contents

Claims framework · cosmetic vs drug line

Lo que puedes decir · lo que no puedes.

5 risks específicos LatAm · labeling + claims

5 risks LatAm-específicos · operativos.

Spanish-English translation

Formaldehyde category

Legacy labels

Botanical marketing

California Prop 65

Quartet cerrado. 4 obligations. 4 ediciones. 1 doctrine.

Leave A Comment Cancelar la respuesta

REDES SOCIALES:

ENLACES

PROGRAMAS

CONTACTANOS